Dicerna Pharmaceuticals Secures $4,000,000 Series B Round

  • Feed Type
  • Date
    10/22/2010
  • Company Name
    Dicerna Pharmaceuticals
  • Mailing Address
    480 Arsenal Street Building 1 Watertown, MA 02472
  • Company Description
    Dicerna Pharmaceuticals is a venture-backed startup developing novel therapeutics in multiple therapeutic areas based on Dicer substrate technology, which makes use of the RNA interference mechanism.
  • Website
    http://www.dicerna.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $4,000,000
  • Transaction Round
    Series B
  • Proceeds Purposes
    Proceeds from the Series B financing will be used to advance Dicerna’s lead in-house program in oncology towards clinical development and progress its other preclinical programs. The company also plans to use the proceeds to continue to develop its delivery technologies, including its proprietary lipid nanoparticle system and novel lipid platform, and targeted delivery systems which combine Dicerna’s DsiRNA molecules with targeting moieties such as peptides, aptamers or antibodies.
  • M&A Terms
  • Venture Investor
    SR One

By posting a comment, you agree to our terms and conditions.